Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Dasatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Sprycel (dasatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Sprycel (dasatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to dasatinib in combination with chemotherapy for the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This indication is based on CA180372 (NCT01460160), a multicenter, multiple-cohort study of pediatric patients with newly diagnosed B-cell precursor Ph+ ALL, where the backbone chemotherapy regimen was AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol.